Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation

Anavex Life Sciences nominated two new independent directors, Gautam Patel and Dr. Adrian Senderowicz, to stand for election at the 2026 Annual Meeting as part of a strategy to refresh the board and oversee the company's progress. The announcement serves as a defense against a proxy solicitation by PVG Asset Management and Patrick Adams, who own 0.35% of outstanding shares and are seeking to replace the entire board. The company also revealed that it terminated former CEO Christopher Missling for cause and appointed Dr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.